Gsk Plc (GSK) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access GSK Annual Balance Sheets →
This balance sheet overview for Gsk Plc spans from Dec 31 2024 to Dec 31 2025, showing how the company's assets, liabilities, and equity have evolved across reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
0 0 0 (Dec 31 2024)
Assets
Cash And Cash Equivalents4,567.95
Liabilities IncludedIn Disposal Groups Classified As Held For Sale-139.00
Cash & Short-term Investments4,428.00
Notes Receivable, Current2,148.00
Other Current Assets12,104.00
Total Current Assets23,545.70
Equipment/Property/Plant Net12,535.29
Goodwill net9,437.10
Intangible Assets0.00
Deferred Tax Assets8,767.44
Other Assets, Noncurrent32,764.59
Total Assets82,185.37
Liabilities
Accounts Payable0.00
Current Tax Liabilities-498.00
Short-term Debt-14,708.00
Total Current Liabilities-15,206.00
Long-term debt-1,023.00
Total Long-term Debt-1,023.00
Deferred Tax Liabilities, Net LI-291.00
Other liabilities, Noncurrent0.00
Total Liabilities-16,520.00
Stockholders' Equity
Other Equity15,383.00
Common Stockholder's Equity15,383.00
Total Stockholder's Equity21,456.03
Liabilities & Stockholder's Equity82,185.37
4 historic quarters locked

Sign in to unlock the full Gsk Plc balance sheet history.

About Gsk Plc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: March 6, 2026
  • Source: gsk-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001131399-26-000004

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.